readthroughSign in
CompanySCYXNasdaqJersey City, NJ

Scynexis Inc

Scynexis develops antifungal compounds and SCY-770, a treatment for autosomal dominant polycystic kidney disease with orphan drug designation.

SCHEDULE 13G/ANov 16Latest SEC filing
Sep 28Latest story